Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer
Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer
复制标题
DOI：
10.1038/s41467-019-13076-7
复制
发表时间：
2019-11-06
影响因子：
16.6
通讯作者：
Rosenthal, Eben L.
中科院分区：
文献类型：
--
作者：
Nishio, Naoki;van den Berg, Nynke S.;Rosenthal, Eben L.
识别淋巴结（LN）转移对于实体瘤的分期至关重要，因此，外科医生专注于在消融手术期间收获大量LN用于病理学评价。分离那些最有可能携带转移性疾病的LN可以允许对较少的LN进行更严格的评估。在这里，我们评估了全身注射的近红外荧光标记的肿瘤靶向造影剂帕尼单抗-IRDye 800 CW的影响，以促进在头颈部癌症患者的离体环境中识别转移性淋巴结。分子成像显示，在接受择期颈清扫术的头颈部癌症患者中，转移性淋巴结的平均荧光信号显著高于良性淋巴结。因此，通过分子成像预先选择高危淋巴结，可以对淋巴结进行更严格的检查，从而改善常规颈淋巴结清扫术的诊断。
Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection.